Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Forbes thinks Pfizer undervalued:
https://www.google.com/amp/s/www.forbes.com/sites/greatspeculations/2020/05/21/why-pfizer-looks-undervalued-at-38/amp/
A scam, lol? You short sellers are really beyond ridiculous. Do you really think Mount Sinai Health System, one of the most highly regarded health systems in the world, would allow this information to be publicized if it were false? It’s understandable that this might go sideways for awhile until human testing can be done with positive results, which could be as early as this summer. I wouldn’t want to be shorting or sitting on the sidelines then.
Remember, fortune favors the bold. Also Dr. Fauci is highly respected in the medical community and has an impeccable record. He is one of the chief reasons why investors are so bullish about Moderna.
I’d prefer to listen to Dr. Fauci than this character. This sounds like a lot of short selling propaganda.
Remember, Gilead had also submitted a new drug application for Filgotinib , a treatment for rheumatoid arthritis, to the FDA last December for priority review after a Phase 3 trial. This could be another major catalyst coming up on top of Remdesivir.
Dr. Anthony Fauci says data from remdesivir coronavirus drug trial shows 'quite good news'
White House health advisor Dr. Anthony Fauci said Wednesday that data from a coronavirus drug trial testing Gilead Sciences' antiviral drug remdesivir showed "quite good news."
Speaking to reporters from the White House, Fauci said he was told data from the trial showed a "clear cut positive effect in diminishing time to recover."
"This will be the standard of care," Fauci, director of the National Institute of Allergy and Infectious Disease, added.
A study of Gilead's remdesivir drug conducted by the National Institute of Allergy and Infectious Diseases met its primary endpoint, the drugmaker said, lifting expectations for a potential coronavirus treatment. Gilead also released the results of its own study, which showed improvement in patients taking remdesivir to treat the virus. Gilead shares jumped 3% after a brief halt in the premarket.
"The idea of something that is just given to you in the hospital IV that makes it so that it eliminates the, let's say, the odds of you dying is something that makes us feel like that maybe this is the Tamiflu for this dreaded disease," said CNBC's Jim Cramer. "I think a lot people are going to say open [the economy] up and that's why the market's flying."
There just seems to be a connection to me, only based on my experience. Now when the analysts downgrade this stock saying “it’s fully valued amid market enthusiasm” when I’ve seen Pharma stocks on the Nasdaq go from $1 to $60 in two days after only passing a phase one trial, then that strikes me as manipulation.
I’m no expert but from what I’ve seen in my ten years of investing is when a Pharma company is putting out a lot of PR’s and interviews about a new drug then lookout. When they’re telling you to be cautious and wait for more data then they’ve most likely got something.
This is a flat out steal at these prices now that they’re finally processing and acquiring contracts. Where will this be a year from now?
Finally news!
Nice post Hmmmmmm, that says it all.
Time to buy more, the run up is coming. Mike knows how to create a profitable business model.
This might address your concerns: MONCTON, New Brunswick--(BUSINESS WIRE)--January 23, 2020--
Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the "Company" or "Organigram"), a leading licensed producer of cannabis, is pleased to announce products from its premium adult recreational Edison Cannabis Co. brand have been awarded top honours in the consumer-driven Leafly Readers Choice Awards.
Yup, nothing like a little Clapton to put things in perspective. I added to my position at 2.12. This is nothing more than a short term setback.
Shaking off the weak hands before compliance on Jan. 31 and reinstatement to follow shortly afterwards. $4-6 U.S. by end of the year. CTST$$
‘Nuff said! lol
Thanks for sharing Dude.
It wouldn’t surprise me.
I’m wondering if the Australian bushfires are having any impact on MediPharm operations in Wonthaggi, which isn’t far from the fire zone. Haven’t heard anything.
Happy New Year and glta! 2020 can only bring continued growth and profitability.
So why the cynicism? Sounds all good to me and we welcome the big boys getting in. By the way the Barrie area does look like a nice area.
They applied on Nov. 5th. According to Quora: “It generally takes 4-6 weeks to process a listing application. This time frame is variable and may be shortened considerably, if the application raises no issues and the company responds to staff comments.” IMHO I think Medif could easily reach $10 US over the next year or two.
I’m just going to quietly hold onto my shares. With Nasdaq, Australia facility, GMP certification, profitability, and the list goes on, it’s only a matter of time before this explodes.
No problem hiroller and thank you for your insightful thoughts on the subject. I’m hoping it goes the other way, with the evidence pointing toward bootleg vape cartridges it will be a boost for legal, tested vaping products.
Vaping ban? I only know of eight U.S. states that have banned vaping. Trump no longer supports a ban on flavored e-cigarettes.
Nice to close in the green when just about everyone else in the sector is red. VGW is the place to be!
I’m hoping it’s only 7 months, Q1 financials.
GMP Certification must be just around the corner. VGW getting ready to breakout!
Yesterday GMP Securities gives Valens a $10 price target. https://www.google.com/amp/s/www.cantechletter.com/2019/07/valens-groworks-has-an-upside-of-172-per-cent-gmp-says/amp/
Good article. Thanks for sharing.
This covers it. New interview with Jeff Fallows.
Old news, it was explained in the CC.
Check out the videos on Valens Groworks Instagram. Ready for liftoff on Friday.
Valens was blindsided today by a Labs PR which I’m sure wasn’t just coincidental. This was overall a very good earnings report and we should see VGW climb back up through the rest of the week IMO.
Already rebounding. The only reason why it went as low as it did was due to TRST screwup and everyone knows that.
Just bought back in. Couldn’t pass up these bargain basement prices. How undervalued is this stock?